Drug targets

Professor Sonika Bhatnagar explores how artificial intelligence is enabling drug discovery at rates never seen before. A bullet for cure The year was 1907, and Paul Ehrlich, the German Nobel laureate had proposed the idea of a magic bullet to cure diseases. The magic in the bullet was that the human at whom it was fired […]

Regenerative medicines in early-stage development have seen a change in drug targets compared to therapies in late-stage development. According to analysts GlobalData, early-stage therapies are now focused on vascular endothelial growth factor (VEGF) as the top drug target, with three drugs currently in development. Surprisingly, the majority of the targets for drugs in early-stage development […]

Salipro Biotech, in collaboration with AstraZeneca, has published data from a study which describes a novel method to directly extract membrane proteins from cells into lipid Salipro nanoparticles, enabling structure-function analysis using surface plasmon resonance (SPR) and cryo-electron microscopy (cryo-EM) for challenging drug targets. The scientists extracted and purified functional membrane proteins directly from cells […]

It’s impossible to be online and not hear about ChatGPT, the controversial chatbot launched by OpenAI in November 2022. Here, DDW’s Diana Spencer takes a look at the ways ChatGPT and technology like it could change the future of drug discovery and development. Chat Generative Pre-Trained Transformer (or ChatGPT) is a conversational chatbot, designed to […]

PhoreMost and ThinkCyte have entered a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI).  The partnership leverages both companies’ technologies in high-throughput drug discovery, PhoreMost’s phenotypic screening platform, SITESEEKER, and ThinkCyte’s AI-driven cell characterisation and sorting platform, Ghost Cytometry.  Driven by advances in cell-based phenotypic screening tools and novel […]

This is the latest episode of the free DDW podcast, “Complex problems require complex solutions”. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “How quantum computing can benefit drug discovery” and “Sitting down with Dr Michael Hayden from Prilenia Therapeutics”. In the first article, Brad […]

A new biotechnology company plans to pioneer the integrated mapping of disease networks for precision therapeutics. Rezo Therapeutics has launched with $78 million from a Series A financing, led by SR One, a16z Bio + Health, and Norwest Venture Partners. The company’s platform is based on technology from the Quantitative Biosciences Institute (QBI) at the […]

Swedish biotech company Salipro Biotech has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target.  The collaboration brings together Salipro Biotech’s services in developing stable antigens of GPCRs, ion channels and transporters via its proprietary platform, with Sanofi’s discovery programmes to identify biologics […]

In a presentation at AIDS 2022, the 24th International AIDS Conference in Montreal, scientists with the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) and their collaborators described how their use of technology revealed insights into cellular reservoirs of HIV and what those observations could mean for the next steps in […]

A new app note, brought to you by BellBrook Labs and supported by DDW, is available to download for free here.  Clinical trials continue to determine whether therapeutic modulation of kinases can be used to suppress the immune system in autoimmune diseases or stimulate for antiviral and cancer immunotherapy. The discovery and characterisation of small molecule modulators have […]